|
|
|
201-500 employees
View all
|
|
Biotechnology
|
|
177-181 Avenue Pierre Brossolette, Montrouge, France 92120, FR
|
|
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
|
DBV Technologies Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
40%
|
The widely used DBV Technologies email format is {first}.{last} (e.g. [email protected]) with 40% adoption across the company.
To contact DBV Technologies customer service number in your country click here to find.
Daniel Tasse is the CEO of DBV Technologies. To contact Daniel Tasse email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.